UPDATE: Cowen & Company Upgraded Ironwood Pharmaceuticals to Outperform

Cowen & Company analyst Edward Nash upgraded Ironwood Pharmaceuticals, Inc. IRWD from Market Perform to Outperform and maintained a $14 PT. Nash noted that the strong early performance of Linzess indicates that it will be a hit. The analyst reported that prescriptions are above Takeda/ Sucampo's Amitiza, and gains in refill rates suggest that patients are satisfied with Linzess. Last month, Piper Jaffrey commented that Irownwood's Linzess would probably not be a “blockbuster.” Ironwood closed at $9.95 on Wednesday and is currently trading +2.71%.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsCowen & CompanyEdward Nash
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!